Keywords: Europe, Committee for Orphan Medicinal Products, EMA, International interactions, HTAs

EMA Committee for Orphan Medicinal Products - strengthened interactions with patients and international partners

Article | 17 February 2013

"The European Medicines Agency’s Committee for Orphan Medicinal Products (COMP) is stepping into another stage of its role ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in